Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Andy Griffith’s showbiz status endures
Few entertainers have stayed in the nation’s collective conscience like Andy Griffith. Griffith is best known for his warm and wise television portrayals of Sheriff...
Thu Jul 9, 2026

Tar Heel hoists the Stanley Cup — twice
Mallory Wilmoth knows how much the Stanley Cup weighs. It’s about 35 pounds and can be cumbersome to lift, especially while standing on ice in...
Wed Jul 8, 2026

UNC student, Rhodes scholar brings hope back home to Jamaica
When Tiana Dinham flew home to Jamaica in November 2025, the University of North Carolina senior experienced the “lowest of lows and highest of highs.”...
Tue Jul 7, 2026

How Chapel Hill will use parking to keep a homegrown robotics company downtown
As an advanced robotics and precision software company working with health care, logistics, manufacturing and hospitality users, Blue Sky Robotics Inc. has high-growth opportunities, said...
Sun Jul 5, 2026